<DOC>
	<DOCNO>NCT01260506</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability efficacy VB-111 patient Relapsed Glioblastoma Multiforme .</brief_summary>
	<brief_title>Single-Arm Open-Label Multicenter Study VB-111 Patients With Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Subjects must histologically confirm diagnosis glioblastoma multiforme gliosarcoma ; 2 . Measurable disease RANO criterion ; 3 . Disease progression recurrence follow standard care treatment temozolomide radiation ; 4 . An interval least 4 week prior surgical resection study enrollment ; 5 . An interval least 12 week prior radiotherapy least 4 week prior chemotherapy , enrollment protocol ; 6 . Recovered Grade 1 less toxic effect earlier intervention ; 7 . Karnofsky performance status &gt; 60 % 1 . Prior antiangiogenic therapy include VEGF sequester agent ( ie bevacizumab , aflibercept , etc ) VEGFR inhibitor ( cediranib , pazopanib , sunitinib , sorafenib , etc ) ; 2 . Prior stereotactic radiotherapy ; 3 . Active infection ; 4 . Evidence CNS haemorrhage CTCAE grade 2 baseline MRI ; 5 . Subjects suffer acute cardiac event within last 12 month ; 6 . Subjects active vascular disease , either myocardial peripheral ; 7 . Subjects proliferative and/or vascular retinopathy ; 8 . Subjects know active second malignancy ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Relapsed Glioblastoma Multiforme , GBM</keyword>
</DOC>